Matches in SemOpenAlex for { <https://semopenalex.org/work/W3008672674> ?p ?o ?g. }
Showing items 1 to 98 of
98
with 100 items per page.
- W3008672674 abstract "e17081 Background: Biomarkers to select mRCC patients most likely to benefit to immunotherapy are needed. The retrospective multicentre Meet-URO-15 study evaluated the prognostic role of peripheral blood cells in mRCC patients treated with Nivolumab. Methods: Complete blood count was assessed at the first four cycles of Nivolumab. The primary endpoint was median overall survival (mOS) according to bNLR. NLR was defined as neutrophil / lymphocyte (cutoff = 3) and ΔNLR the difference between NLR at 2 nd cycle and bNLR (median as cutoff = 1.1). Results: From October 2015 to October 2019, 470 patients started Nivolumab as 2 nd (67%), 3 rd (22%) and > 3 rd (11%) line. Median age was 66 years, 71% were male and 83% had clear cell histology. Baseline IMDC group was favorable in 25%, intermediate in 63% and poor in 12%. Lymph-nodes, visceral and bone metastases were present in 54%, 91% and 36%. mOS and progression-free survival (PFS) were 34.8 and 7.5 months. Overall response rate (ORR) and disease control rate (DCR) were 30% and 61%. bNLR was available in 404 patients: bNLR < 3 (54%) correlated with statistically significant longer PFS [11.4 vs 5.4 months; HR 1.69 (1.33-2.15)] and OS [46.2 vs 17.2 months; HR 2.37 (1.72-3.26)] (both p< 0.001), with similar ORR (35% vs 30%, p= 0.28) but higher DCR (71% vs 52%, p< 0.001). ΔNLR was available in 360 patients: ΔNLR < 1.1 (73%) correlated with a statistically significant improvement of PFS [11.2 vs 4.9 months; HR 1.53 (1.16-2.03), p= 0.03], OS [Not Reached vs 19.7 months; HR 1.83 (1.28-2.61), p= 0.001], ORR (37% vs 23%, p= 0.011) and DCR (68% vs 53%, p= 0.008). Multivariate analyses adjusted for IMDC group, line of therapy and metastatic sites, confirmed the statistically significant correlation of bNLR and ΔNLR with OS, PFS and DCR. Conclusions: Our study showed the statistically significant correlation of lower bNLR and early ΔNLR with longer OS, PFS and higher DCR in mRCC patients treated with Nivolumab." @default.
- W3008672674 created "2020-03-06" @default.
- W3008672674 creator A5005499943 @default.
- W3008672674 creator A5010573143 @default.
- W3008672674 creator A5012176145 @default.
- W3008672674 creator A5012508480 @default.
- W3008672674 creator A5013913173 @default.
- W3008672674 creator A5018378600 @default.
- W3008672674 creator A5021477463 @default.
- W3008672674 creator A5028388712 @default.
- W3008672674 creator A5034433849 @default.
- W3008672674 creator A5041434581 @default.
- W3008672674 creator A5047135191 @default.
- W3008672674 creator A5050343624 @default.
- W3008672674 creator A5057926104 @default.
- W3008672674 creator A5060954139 @default.
- W3008672674 creator A5061243125 @default.
- W3008672674 creator A5062273587 @default.
- W3008672674 creator A5063795761 @default.
- W3008672674 creator A5071060598 @default.
- W3008672674 creator A5077284495 @default.
- W3008672674 creator A5081355165 @default.
- W3008672674 date "2020-05-20" @default.
- W3008672674 modified "2023-10-14" @default.
- W3008672674 title "Baseline and early change of neutrophil to lymphocyte ratio (bNLR and ΔNLR) as prognostic factors in metastatic renal cell carcinoma (mRCC) treated with Nivolumab: Final results of the Meet-URO 15 (I-BIO-REC) study." @default.
- W3008672674 doi "https://doi.org/10.1200/jco.2020.38.15_suppl.e17081" @default.
- W3008672674 hasPublicationYear "2020" @default.
- W3008672674 type Work @default.
- W3008672674 sameAs 3008672674 @default.
- W3008672674 citedByCount "0" @default.
- W3008672674 crossrefType "journal-article" @default.
- W3008672674 hasAuthorship W3008672674A5005499943 @default.
- W3008672674 hasAuthorship W3008672674A5010573143 @default.
- W3008672674 hasAuthorship W3008672674A5012176145 @default.
- W3008672674 hasAuthorship W3008672674A5012508480 @default.
- W3008672674 hasAuthorship W3008672674A5013913173 @default.
- W3008672674 hasAuthorship W3008672674A5018378600 @default.
- W3008672674 hasAuthorship W3008672674A5021477463 @default.
- W3008672674 hasAuthorship W3008672674A5028388712 @default.
- W3008672674 hasAuthorship W3008672674A5034433849 @default.
- W3008672674 hasAuthorship W3008672674A5041434581 @default.
- W3008672674 hasAuthorship W3008672674A5047135191 @default.
- W3008672674 hasAuthorship W3008672674A5050343624 @default.
- W3008672674 hasAuthorship W3008672674A5057926104 @default.
- W3008672674 hasAuthorship W3008672674A5060954139 @default.
- W3008672674 hasAuthorship W3008672674A5061243125 @default.
- W3008672674 hasAuthorship W3008672674A5062273587 @default.
- W3008672674 hasAuthorship W3008672674A5063795761 @default.
- W3008672674 hasAuthorship W3008672674A5071060598 @default.
- W3008672674 hasAuthorship W3008672674A5077284495 @default.
- W3008672674 hasAuthorship W3008672674A5081355165 @default.
- W3008672674 hasConcept C121608353 @default.
- W3008672674 hasConcept C126322002 @default.
- W3008672674 hasConcept C126894567 @default.
- W3008672674 hasConcept C146357865 @default.
- W3008672674 hasConcept C151730666 @default.
- W3008672674 hasConcept C203092338 @default.
- W3008672674 hasConcept C2777472916 @default.
- W3008672674 hasConcept C2777701055 @default.
- W3008672674 hasConcept C2780030458 @default.
- W3008672674 hasConcept C2780739268 @default.
- W3008672674 hasConcept C3019894029 @default.
- W3008672674 hasConcept C535046627 @default.
- W3008672674 hasConcept C71924100 @default.
- W3008672674 hasConcept C86803240 @default.
- W3008672674 hasConcept C90924648 @default.
- W3008672674 hasConceptScore W3008672674C121608353 @default.
- W3008672674 hasConceptScore W3008672674C126322002 @default.
- W3008672674 hasConceptScore W3008672674C126894567 @default.
- W3008672674 hasConceptScore W3008672674C146357865 @default.
- W3008672674 hasConceptScore W3008672674C151730666 @default.
- W3008672674 hasConceptScore W3008672674C203092338 @default.
- W3008672674 hasConceptScore W3008672674C2777472916 @default.
- W3008672674 hasConceptScore W3008672674C2777701055 @default.
- W3008672674 hasConceptScore W3008672674C2780030458 @default.
- W3008672674 hasConceptScore W3008672674C2780739268 @default.
- W3008672674 hasConceptScore W3008672674C3019894029 @default.
- W3008672674 hasConceptScore W3008672674C535046627 @default.
- W3008672674 hasConceptScore W3008672674C71924100 @default.
- W3008672674 hasConceptScore W3008672674C86803240 @default.
- W3008672674 hasConceptScore W3008672674C90924648 @default.
- W3008672674 hasLocation W30086726741 @default.
- W3008672674 hasOpenAccess W3008672674 @default.
- W3008672674 hasPrimaryLocation W30086726741 @default.
- W3008672674 hasRelatedWork W1202678 @default.
- W3008672674 hasRelatedWork W13397619 @default.
- W3008672674 hasRelatedWork W1411949 @default.
- W3008672674 hasRelatedWork W14169641 @default.
- W3008672674 hasRelatedWork W17022311 @default.
- W3008672674 hasRelatedWork W2970022 @default.
- W3008672674 hasRelatedWork W306651 @default.
- W3008672674 hasRelatedWork W61283 @default.
- W3008672674 hasRelatedWork W6476279 @default.
- W3008672674 hasRelatedWork W6776275 @default.
- W3008672674 isParatext "false" @default.
- W3008672674 isRetracted "false" @default.
- W3008672674 magId "3008672674" @default.
- W3008672674 workType "article" @default.